Do analysts prefer ABVC or ZYBT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ABVC BioPharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Zhengye Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, ABVC or ZYBT?

ABVC BioPharma has higher earnings, but lower revenue than Zhengye Biotechnology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ABVC BioPharma $510K 50.17 -$7.91M -$0.30 N/A Zhengye Biotechnology $16.64M 4.59 -$9.98M N/A N/A

Is ABVC or ZYBT more profitable?

Zhengye Biotechnology's return on equity of 0.00% beat ABVC BioPharma's return on equity. Company Net Margins Return on Equity Return on Assets ABVC BioPharma N/A -47.68% -30.97% Zhengye Biotechnology N/A N/A N/A

Do analysts prefer ABVC or CING?

Cingulate has a consensus target price of $27.00, suggesting a potential upside of 429.41%. Given Cingulate's stronger consensus rating and higher probable upside, analysts clearly believe Cingulate is more favorable than ABVC BioPharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ABVC BioPharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cingulate 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Is ABVC or CING more profitable?

ABVC BioPharma's return on equity of -47.68% beat Cingulate's return on equity. Company Net Margins Return on Equity Return on Assets ABVC BioPharma N/A -47.68% -30.97% Cingulate N/A -238.40% -128.67%

Do analysts prefer LONA or ABVC?

Athira Pharma currently has a consensus price target of $17.33, indicating a potential upside of 129.28%. Given Athira Pharma's stronger consensus rating and higher possible upside, equities research analysts clearly believe Athira Pharma is more favorable than ABVC BioPharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Athira Pharma 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50 ABVC BioPharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is LONA or ABVC more profitable?

ABVC BioPharma's return on equity of -47.68% beat Athira Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Athira Pharma N/A -411.58% -225.73% ABVC BioPharma N/A -47.68% -30.97%

Does the media prefer LONA or ABVC?

In the previous week, Athira Pharma had 3 more articles in the media than ABVC BioPharma. MarketBeat recorded 4 mentions for Athira Pharma and 1 mentions for ABVC BioPharma. Athira Pharma's average media sentiment score of 0.34 beat ABVC BioPharma's score of 0.00 indicating that Athira Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Athira Pharma 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ABVC BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer MNOV or ABVC?

MediciNova presently has a consensus target price of $8.33, indicating a potential upside of 411.25%. Given MediciNova's stronger consensus rating and higher possible upside, research analysts clearly believe MediciNova is more favorable than ABVC BioPharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MediciNova 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.67 ABVC BioPharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor MNOV or ABVC?

In the previous week, MediciNova had 2 more articles in the media than ABVC BioPharma. MarketBeat recorded 3 mentions for MediciNova and 1 mentions for ABVC BioPharma. MediciNova's average media sentiment score of 0.81 beat ABVC BioPharma's score of 0.00 indicating that MediciNova is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MediciNova 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ABVC BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer SPRO or ABVC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spero Therapeutics 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 ABVC BioPharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor SPRO or ABVC?

In the previous week, Spero Therapeutics had 1 more articles in the media than ABVC BioPharma. MarketBeat recorded 2 mentions for Spero Therapeutics and 1 mentions for ABVC BioPharma. Spero Therapeutics' average media sentiment score of 0.23 beat ABVC BioPharma's score of 0.00 indicating that Spero Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spero Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ABVC BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

ABVC BioPharma (ABVC) Competitors

$0.96 0.00 (0.00%)

As of 09/4/2026 04:00 PM Eastern

Compare

ABVC vs. ZYBT, CING, LONA, MNOV, and SPRO

Should you buy ABVC BioPharma stock or one of its competitors? ABVC BioPharma's main competitors and comparable companies include Zhengye Biotechnology (ZYBT), Cingulate (CING), Athira Pharma (LONA), MediciNova (MNOV), and Spero Therapeutics (SPRO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does ABVC BioPharma compare to Zhengye Biotechnology?

ABVC BioPharma (NASDAQ:ABVC) and Zhengye Biotechnology (NASDAQ:ZYBT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, valuation, risk, dividends, analyst recommendations and institutional ownership.

ABVC BioPharma has higher earnings, but lower revenue than Zhengye Biotechnology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ABVC BioPharma	$510K	50.17	-$7.91M	-$0.30	N/A
Zhengye Biotechnology	$16.64M	4.59	-$9.98M	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

11.4% of ABVC BioPharma shares are held by institutional investors. 19.0% of ABVC BioPharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Zhengye Biotechnology's return on equity of 0.00% beat ABVC BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ABVC BioPharma	N/A	-47.68%	-30.97%
Zhengye Biotechnology	N/A	N/A	N/A

In the previous week, ABVC BioPharma had 1 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 1 mentions for ABVC BioPharma and 0 mentions for Zhengye Biotechnology. ABVC BioPharma's average media sentiment score of 0.00 equaled Zhengye Biotechnology'saverage media sentiment score.

Company	Overall Sentiment
ABVC BioPharma	Neutral
Zhengye Biotechnology	Neutral

ABVC BioPharma has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market. Comparatively, Zhengye Biotechnology has a beta of -2.56, suggesting that its share price is 356% less volatile than the broader market.

Summary

ABVC BioPharma beats Zhengye Biotechnology on 6 of the 9 factors compared between the two stocks.

How does ABVC BioPharma compare to Cingulate?

ABVC BioPharma (NASDAQ:ABVC) and Cingulate (NASDAQ:CING) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, institutional ownership, earnings, media sentiment, dividends, valuation, analyst recommendations and profitability.

In the previous week, ABVC BioPharma had 1 more articles in the media than Cingulate. MarketBeat recorded 1 mentions for ABVC BioPharma and 0 mentions for Cingulate. ABVC BioPharma's average media sentiment score of 0.00 equaled Cingulate'saverage media sentiment score.

Company	Overall Sentiment
ABVC BioPharma	Neutral
Cingulate	Neutral

ABVC BioPharma has a beta of 0.61, indicating that its share price is 39% less volatile than the broader market. Comparatively, Cingulate has a beta of -0.88, indicating that its share price is 188% less volatile than the broader market.

11.4% of ABVC BioPharma shares are held by institutional investors. Comparatively, 41.3% of Cingulate shares are held by institutional investors. 19.0% of ABVC BioPharma shares are held by insiders. Comparatively, 5.3% of Cingulate shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Cingulate has a consensus target price of $27.00, suggesting a potential upside of 429.41%. Given Cingulate's stronger consensus rating and higher probable upside, analysts clearly believe Cingulate is more favorable than ABVC BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cingulate	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

ABVC BioPharma has higher revenue and earnings than Cingulate. ABVC BioPharma is trading at a lower price-to-earnings ratio than Cingulate, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ABVC BioPharma	$510K	50.17	-$7.91M	-$0.30	N/A
Cingulate	N/A	N/A	-$22.45M	-$3.59	N/A

ABVC BioPharma's return on equity of -47.68% beat Cingulate's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ABVC BioPharma	N/A	-47.68%	-30.97%
Cingulate	N/A	-238.40%	-128.67%

Summary

ABVC BioPharma beats Cingulate on 8 of the 13 factors compared between the two stocks.

How does ABVC BioPharma compare to Athira Pharma?

Athira Pharma (NASDAQ:LONA) and ABVC BioPharma (NASDAQ:ABVC) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation, profitability and media sentiment.

ABVC BioPharma has higher revenue and earnings than Athira Pharma. ABVC BioPharma is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athira Pharma	N/A	N/A	-$105.61M	-$4.21	N/A
ABVC BioPharma	$510K	50.17	-$7.91M	-$0.30	N/A

Athira Pharma has a beta of 2.05, meaning that its share price is 105% more volatile than the broader market. Comparatively, ABVC BioPharma has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market.

Athira Pharma currently has a consensus price target of $17.33, indicating a potential upside of 129.28%. Given Athira Pharma's stronger consensus rating and higher possible upside, equities research analysts clearly believe Athira Pharma is more favorable than ABVC BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

57.1% of Athira Pharma shares are owned by institutional investors. Comparatively, 11.4% of ABVC BioPharma shares are owned by institutional investors. 25.7% of Athira Pharma shares are owned by insiders. Comparatively, 19.0% of ABVC BioPharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

ABVC BioPharma's return on equity of -47.68% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Athira Pharma	N/A	-411.58%	-225.73%
ABVC BioPharma	N/A	-47.68%	-30.97%

In the previous week, Athira Pharma had 3 more articles in the media than ABVC BioPharma. MarketBeat recorded 4 mentions for Athira Pharma and 1 mentions for ABVC BioPharma. Athira Pharma's average media sentiment score of 0.34 beat ABVC BioPharma's score of 0.00 indicating that Athira Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Athira Pharma	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ABVC BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Athira Pharma beats ABVC BioPharma on 9 of the 14 factors compared between the two stocks.

How does ABVC BioPharma compare to MediciNova?

MediciNova (NASDAQ:MNOV) and ABVC BioPharma (NASDAQ:ABVC) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations, institutional ownership and media sentiment.

MediciNova has a beta of 0.63, meaning that its stock price is 37% less volatile than the broader market. Comparatively, ABVC BioPharma has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market.

ABVC BioPharma has a net margin of 0.00% compared to MediciNova's net margin of -1,168.70%. MediciNova's return on equity of -26.51% beat ABVC BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MediciNova	-1,168.70%	-26.51%	-24.39%
ABVC BioPharma	N/A	-47.68%	-30.97%

In the previous week, MediciNova had 2 more articles in the media than ABVC BioPharma. MarketBeat recorded 3 mentions for MediciNova and 1 mentions for ABVC BioPharma. MediciNova's average media sentiment score of 0.81 beat ABVC BioPharma's score of 0.00 indicating that MediciNova is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MediciNova	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ABVC BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

9.9% of MediciNova shares are held by institutional investors. Comparatively, 11.4% of ABVC BioPharma shares are held by institutional investors. 14.0% of MediciNova shares are held by company insiders. Comparatively, 19.0% of ABVC BioPharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

ABVC BioPharma has higher revenue and earnings than MediciNova. MediciNova is trading at a lower price-to-earnings ratio than ABVC BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediciNova	$410K	195.68	-$12M	-$0.21	N/A
ABVC BioPharma	$510K	50.17	-$7.91M	-$0.30	N/A

MediciNova presently has a consensus target price of $8.33, indicating a potential upside of 411.25%. Given MediciNova's stronger consensus rating and higher possible upside, research analysts clearly believe MediciNova is more favorable than ABVC BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MediciNova	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

MediciNova beats ABVC BioPharma on 11 of the 17 factors compared between the two stocks.

How does ABVC BioPharma compare to Spero Therapeutics?

Spero Therapeutics (NASDAQ:SPRO) and ABVC BioPharma (NASDAQ:ABVC) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership and profitability.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spero Therapeutics	0 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Spero Therapeutics had 1 more articles in the media than ABVC BioPharma. MarketBeat recorded 2 mentions for Spero Therapeutics and 1 mentions for ABVC BioPharma. Spero Therapeutics' average media sentiment score of 0.23 beat ABVC BioPharma's score of 0.00 indicating that Spero Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spero Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ABVC BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Spero Therapeutics has a net margin of 24.90% compared to ABVC BioPharma's net margin of 0.00%. Spero Therapeutics' return on equity of 16.17% beat ABVC BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spero Therapeutics	24.90%	16.17%	12.57%
ABVC BioPharma	N/A	-47.68%	-30.97%

25.6% of Spero Therapeutics shares are held by institutional investors. Comparatively, 11.4% of ABVC BioPharma shares are held by institutional investors. 2.9% of Spero Therapeutics shares are held by company insiders. Comparatively, 19.0% of ABVC BioPharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Spero Therapeutics has a beta of 1.49, meaning that its share price is 49% more volatile than the broader market. Comparatively, ABVC BioPharma has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market.

Spero Therapeutics has higher revenue and earnings than ABVC BioPharma. ABVC BioPharma is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spero Therapeutics	$66.80M	1.05	$8.57M	$0.11	11.00
ABVC BioPharma	$510K	50.17	-$7.91M	-$0.30	N/A

Summary

Spero Therapeutics beats ABVC BioPharma on 12 of the 14 factors compared between the two stocks.

Get ABVC BioPharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABVC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABVC vs. The Competition

Export

Metric	ABVC BioPharma	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$25.59M	$12.19B	$7.21B	$12.89B
Dividend Yield	N/A	2.59%	2.54%	9.13%
P/E Ratio	-3.20	792.20	273.84	25.45
Price / Sales	50.17	760.84	625.56	100.83
Price / Cash	N/A	15.18	28.92	35.62
Price / Book	1.85	11.09	11.01	6.39
Net Income	-$7.91M	$2.83B	$3.49B	$358.69M
7 Day Performance	11.97%	4.42%	1.63%	0.22%
1 Month Performance	-5.87%	6.88%	4.42%	-0.10%
1 Year Performance	-63.77%	10.00%	24.21%	14.04%

ABVC BioPharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABVC ABVC BioPharma	0.3712 of 5 stars	$0.96 flat	N/A	-63.8%	$25.59M	$510K	N/A	30	News Coverage Gap Up
ZYBT Zhengye Biotechnology	0.1283 of 5 stars	$1.63 -1.2%	N/A	-80.3%	$78.20M	$16.64M	N/A	278	Gap Down
CING Cingulate	2.2515 of 5 stars	$5.15 +0.8%	$27.00 +424.3%	+30.8%	$74.31M	N/A	N/A	20
LONA Athira Pharma	3.5235 of 5 stars	$7.67 +1.1%	$17.33 +126.0%	N/A	$71.30M	N/A	N/A	40	Gap Up
MNOV MediciNova	1.9844 of 5 stars	$1.43 -0.7%	$8.33 +482.8%	+26.4%	$70.88M	$410K	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ABVC) was last updated on 9/7/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ABVC BioPharma (ABVC) Competitors

ABVC vs. ZYBT, CING, LONA, MNOV, and SPRO

How does ABVC BioPharma compare to Zhengye Biotechnology?

Summary

How does ABVC BioPharma compare to Cingulate?

Summary

How does ABVC BioPharma compare to Athira Pharma?

Summary

How does ABVC BioPharma compare to MediciNova?

Summary

How does ABVC BioPharma compare to Spero Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABVC vs. The Competition

ABVC BioPharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ABVC BioPharma (ABVC) Competitors

ABVC vs. ZYBT, CING, LONA, MNOV, and SPRO

How does ABVC BioPharma compare to Zhengye Biotechnology?

Which has preferable valuation & earnings, ABVC or ZYBT?

Do analysts prefer ABVC or ZYBT?

Do insiders & institutionals hold more shares of ABVC or ZYBT?

Is ABVC or ZYBT more profitable?

Does the media prefer ABVC or ZYBT?

Which has more volatility and risk, ABVC or ZYBT?

Summary

How does ABVC BioPharma compare to Cingulate?

Does the media favor ABVC or CING?

Which has more volatility & risk, ABVC or CING?

Do insiders and institutionals have more ownership in ABVC or CING?

Do analysts prefer ABVC or CING?

Which has higher valuation & earnings, ABVC or CING?

Is ABVC or CING more profitable?

Summary

How does ABVC BioPharma compare to Athira Pharma?

Which has preferable valuation and earnings, LONA or ABVC?

Which has more risk & volatility, LONA or ABVC?

Do analysts prefer LONA or ABVC?

Do institutionals and insiders have more ownership in LONA or ABVC?

Is LONA or ABVC more profitable?

Does the media prefer LONA or ABVC?

Summary

How does ABVC BioPharma compare to MediciNova?

Which has more risk and volatility, MNOV or ABVC?

Is MNOV or ABVC more profitable?

Does the media favor MNOV or ABVC?

Do insiders & institutionals hold more shares of MNOV or ABVC?

Which has stronger valuation and earnings, MNOV or ABVC?

Do analysts prefer MNOV or ABVC?

Summary

How does ABVC BioPharma compare to Spero Therapeutics?

Do analysts prefer SPRO or ABVC?

Does the media favor SPRO or ABVC?

Is SPRO or ABVC more profitable?

Do institutionals and insiders hold more shares of SPRO or ABVC?

Which has more volatility and risk, SPRO or ABVC?

Which has better earnings & valuation, SPRO or ABVC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABVC vs. The Competition

ABVC BioPharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools